FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000532974> ?p ?o ?g. }

• W2000532974 endingPage "21" @default.
• W2000532974 startingPage "15" @default.
• W2000532974 abstract "In this article, 2 leading physicians debate the strength of outcome data on the efficacy of angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II receptor blockers (ARBs) for reducing the incidence of cardiovascular, cerebrovascular, and renovascular events. Dr. Stephen G. Ball notes that the efficacy of ACE inhibitors for reducing the risk for myocardial infarction independent of their effects on blood pressure is controversial. In the Heart Outcomes Prevention Evaluation (HOPE) study, ramipril treatment in high-risk patients was associated with a 20% reduction in the risk for myocardial infarction; mean reduction in blood pressure was 3 mm Hg for systolic blood pressure and 1 mm Hg for diastolic blood pressure. The HOPE investigators propose that the 20% reduction was much greater than would be expected based on the observed blood pressure reduction. However, a meta-regression analysis of blood pressure reduction in >20 antihypertensive therapy outcome trials found that the reduction in myocardial infarction risk with ramipril observed in HOPE was consistent with the modest blood pressure reduction seen with that agent. Nevertheless, there are convincing data for prevention of myocardial infarction with ACE inhibitors in patients with heart failure, including those with heart failure after myocardial infarction, as well as supportive evidence from studies in patients with diabetes mellitus and concomitant hypertension. On the other hand, Dr. William B. White takes the position that ARBs are well-tolerated antihypertensive agents that specifically antagonize the angiotensin II type 1 (AT(1)) receptor and provide a more complete block of the pathologic effects of angiotensin II-which are mediated via the AT(1) receptor-than ACE inhibitors. The Evaluation of Losartan in the Elderly (ELITE) II study and the Valsartan Heart Failure Trial (ValHeFT) suggest that ARBs reduce the risk for mortality in patients with congestive heart failure. The Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension trial also demonstrated beneficial effects of ARBs in the prevention of stroke events. The Irbesartan in Patients with Diabetes and Microalbuminuria (IRMA) study, the Irbesartan Diabetic Nephropathy Trial (IDNT), and the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated significant reductions in the rate of progression of renal disease in patients receiving ARBs, independent of effects on blood pressure. These data support the use of ARBs, in addition to the standard of care, in hypertensive patients with heart failure who are intolerant of ACE inhibitors, and also provide compelling evidence for their use in patients with hypertension and type 2 diabetes." @default.
• W2000532974 created "2016-06-24" @default.
• W2000532974 creator A5056816871 @default.
• W2000532974 creator A5074396459 @default.
• W2000532974 date "2003-05-01" @default.
• W2000532974 modified "2023-10-18" @default.
• W2000532974 title "Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers—a gap in evidence-based medicine" @default.
• W2000532974 cites W1592471891 @default.
• W2000532974 cites W180946569 @default.
• W2000532974 cites W1969639525 @default.
• W2000532974 cites W1991306589 @default.
• W2000532974 cites W2008292738 @default.
• W2000532974 cites W2023635006 @default.
• W2000532974 cites W2040318629 @default.
• W2000532974 cites W2044773944 @default.
• W2000532974 cites W2050419744 @default.
• W2000532974 cites W2055123579 @default.
• W2000532974 cites W2056893352 @default.
• W2000532974 cites W2056976690 @default.
• W2000532974 cites W2100082183 @default.
• W2000532974 cites W2102979143 @default.
• W2000532974 cites W2125442778 @default.
• W2000532974 cites W2128139183 @default.
• W2000532974 cites W2133217116 @default.
• W2000532974 cites W2138119952 @default.
• W2000532974 cites W2139805666 @default.
• W2000532974 cites W2170912509 @default.
• W2000532974 cites W2297753288 @default.
• W2000532974 cites W2312999996 @default.
• W2000532974 cites W2615684303 @default.
• W2000532974 cites W3021250193 @default.
• W2000532974 cites W3145527833 @default.
• W2000532974 cites W3198570063 @default.
• W2000532974 cites W4239943088 @default.
• W2000532974 cites W4293085726 @default.
• W2000532974 doi "https://doi.org/10.1016/s0002-9149(03)00228-5" @default.
• W2000532974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12781904" @default.
• W2000532974 hasPublicationYear "2003" @default.
• W2000532974 type Work @default.
• W2000532974 sameAs 2000532974 @default.
• W2000532974 citedByCount "20" @default.
• W2000532974 countsByYear W20005329742013 @default.
• W2000532974 countsByYear W20005329742014 @default.
• W2000532974 countsByYear W20005329742016 @default.
• W2000532974 countsByYear W20005329742017 @default.
• W2000532974 countsByYear W20005329742021 @default.
• W2000532974 crossrefType "journal-article" @default.
• W2000532974 hasAuthorship W2000532974A5056816871 @default.
• W2000532974 hasAuthorship W2000532974A5074396459 @default.
• W2000532974 hasConcept C126322002 @default.
• W2000532974 hasConcept C134018914 @default.
• W2000532974 hasConcept C164705383 @default.
• W2000532974 hasConcept C27016395 @default.
• W2000532974 hasConcept C2778198053 @default.
• W2000532974 hasConcept C2779888176 @default.
• W2000532974 hasConcept C2908929049 @default.
• W2000532974 hasConcept C500558357 @default.
• W2000532974 hasConcept C555293320 @default.
• W2000532974 hasConcept C71924100 @default.
• W2000532974 hasConcept C84393581 @default.
• W2000532974 hasConceptScore W2000532974C126322002 @default.
• W2000532974 hasConceptScore W2000532974C134018914 @default.
• W2000532974 hasConceptScore W2000532974C164705383 @default.
• W2000532974 hasConceptScore W2000532974C27016395 @default.
• W2000532974 hasConceptScore W2000532974C2778198053 @default.
• W2000532974 hasConceptScore W2000532974C2779888176 @default.
• W2000532974 hasConceptScore W2000532974C2908929049 @default.
• W2000532974 hasConceptScore W2000532974C500558357 @default.
• W2000532974 hasConceptScore W2000532974C555293320 @default.
• W2000532974 hasConceptScore W2000532974C71924100 @default.
• W2000532974 hasConceptScore W2000532974C84393581 @default.
• W2000532974 hasIssue "10" @default.
• W2000532974 hasLocation W20005329741 @default.
• W2000532974 hasLocation W20005329742 @default.
• W2000532974 hasOpenAccess W2000532974 @default.
• W2000532974 hasPrimaryLocation W20005329741 @default.
• W2000532974 hasRelatedWork W1864361583 @default.
• W2000532974 hasRelatedWork W2041312552 @default.
• W2000532974 hasRelatedWork W2043311409 @default.
• W2000532974 hasRelatedWork W2072325993 @default.
• W2000532974 hasRelatedWork W2084223257 @default.
• W2000532974 hasRelatedWork W2104437520 @default.
• W2000532974 hasRelatedWork W2188351982 @default.
• W2000532974 hasRelatedWork W2289755325 @default.
• W2000532974 hasRelatedWork W2334396920 @default.
• W2000532974 hasRelatedWork W2335083084 @default.
• W2000532974 hasVolume "91" @default.
• W2000532974 isParatext "false" @default.
• W2000532974 isRetracted "false" @default.
• W2000532974 magId "2000532974" @default.
• W2000532974 workType "article" @default.